Barclays initiated coverage on Orchestra BioMed with a new price target
$OBIO
Medicinal Chemicals and Botanical Products
Health Care
Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $12.00 | Buy | BTIG Research |
| 1/2/2025 | $16.00 | Overweight | Barclays |
| 8/22/2024 | $14.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $15.00 | Buy | B. Riley Securities |
| 1/19/2024 | $14.00 | Buy | Jefferies |
| 2/24/2023 | $15.00 | Overweight | Piper Sandler |
| 2/7/2023 | $20.00 | Buy | Chardan Capital Markets |
10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation ("AVIM") therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejection fraction ("HFpEF")Hypertension is the leading cause of diastolic dysfunction and the most common comorbidity in older patients indicated for a pacemaker NEW HOPE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the publication
Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved multiple FDA regulatory milestones: Breakthrough Device Designation for AVIM therapy; approval for expanded BACKBEAT study enrollment criteria, and IDE approval for a U.S. pivotal Virtue SAB trial versus commercially available paclitaxel-coated balloon NEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients t
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study ("BACKBEAT study"), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original study protocolExpanded eligibility criteria now include screening of any hypertensive patients who have received or are scheduled to receive a Medtronic Azure™ or Astra™ pacemaker, including device replacements NEW HOPE, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sh
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for
The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a
Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc
BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00
Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00
H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00